Cargando…
The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice
Alzheimer’s disease (AD) is the most common form of dementia. In particular, neuroinflammation, mediated by microglia cells but also through CD8+ T-cells, actively contributes to disease pathology. Leukotrienes are involved in neuroinflammation and in the pathological hallmarks of AD. In consequence...
Autores principales: | Michael, Johanna, Zirknitzer, Julia, Unger, Michael Stefan, Poupardin, Rodolphe, Rieß, Tanja, Paiement, Nadine, Zerbe, Horst, Hutter-Paier, Birgit, Reitsamer, Herbert, Aigner, Ludwig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967180/ https://www.ncbi.nlm.nih.gov/pubmed/33803482 http://dx.doi.org/10.3390/ijms22052782 |
Ejemplares similares
-
The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
por: Aigner, Ludwig, et al.
Publicado: (2020) -
Improved Bioavailability of Montelukast through a Novel Oral Mucoadhesive Film in Humans and Mice
por: Michael, Johanna, et al.
Publicado: (2020) -
Leukotriene Signaling as a Target in α-Synucleinopathies
por: Strempfl, Katharina, et al.
Publicado: (2022) -
The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies
por: Marschallinger, Julia, et al.
Publicado: (2020) -
Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease
por: Wallin, Johan, et al.
Publicado: (2021)